Additionally, the development of targeted therapies such as gefitinib for EGFR, salirasib for KRAS, and O6-benzylguanine for MGMT has failed to confer significant therapeutic benefits for lung cancer and GBM patients13,15,20, likely due to their inconsistent prognostic and predictive value23. This evidence concerns the gene MGMT and glioblastoma.